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Abstract
Background: Despite increasing reports of the linkage between diabetes and tuberculosis (TB), there is limited
information regarding diabetes and TB drug resistance.
Methods: In this cross-sectional study, sputum and blood samples were collected from 304 adult patients in
rural Andhra Pradesh. Rifampin resistance was assessed by Xpert MTB/RIF (Xpert), and diabetes status was
based on self-report. Additionally, samples were assayed by acid-fast bacilli sputum smear microscopy (AFB)
and QuantiFERON-TB Gold In-Tube (QFT-G), in order to compare relative diagnostic performances.
Results: Among patients with confirmed TB (n = 194), diabetes was associated with 3.0-fold higher risk of
rifampin resistance (95 % CI 1.3–6.7). Considering Xpert MTB/RIF the gold standard, AFB had lower sensitivity
(72.2 vs. 82.5 %) and higher specificity (96.4 vs. 37.0 %) compared to QFT-G for diagnosing TB.
Conclusions: The increased risk of rifampin resistance in patients with diabetes highlights the need for integrated
diabetes surveillance in TB programs, particularly in settings undergoing the epidemiological transition.
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Background
The synergistic interactions between diabetes and tu-
berculosis (TB) are widely recognized [1]. Studies
among patients with TB report associations between
diabetes and adverse outcomes, including mortality, TB
treatment failure and relapse [2]. Moreover, diabetes is
associated with a 3-fold increased risk of active TB, ac-
cording to a systematic review [3].
Globally, TB drug resistance is a growing challenge
to improving TB control; estimates show 480,000 in-
cident cases of multidrug-resistant TB (MDR-TB) in
2013 [4]. In 2013, over 50 % of MDR-TB cases were
reported in India, China, and the Russian Federation
[4]. Worldwide, the treatment success rate of MDR-
TB (48 %) is significantly lower than that among new
TB cases (86 %) [4].
Preliminary evidence from pharmacokinetics studies
suggests that suggests that the linkage between diabetes
and TB drug resistance is biologically plausible. One
study showed reduced rifampin exposure among patients
with TB-diabetes coinfections, compared to those with
TB [5]. Furthermore, another study found that low ab-
sorption of anti-TB treatment (according to area under
the curve [AUC]) was associated with increased drug re-
sistance [6].
Key research gaps include determining the clinical
relevance of potential effects of diabetes on TB drug
resistance, particularly in settings undergoing the epi-
demiological transition [7]. During the shift from in-
fectious to chronic diseases, certain geographic areas
may still have higher prevalence of TB and simultan-
eously rising diabetes incidence. Therefore, our pri-
mary objective was to assess the association between
diabetes mellitus and rifampin resistance among pa-
tients with active TB in South India. Secondarily, we
compared the performance of Xpert MTB/RIF (Xpert)
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with acid-fast bacilli sputum smear microscopy (AFB)
and QuantiFERON-TB Gold In-Tube (QFT-G).
Methods
Study population
In this secondary analysis of cross-sectional data, 304
adult patients were serially enrolled from an outpatient
clinic of a rural hospital in Andhra Pradesh during
2012–13. Hospital physicians referred patients with clin-
ical signs and symptoms of TB. Sputum and blood sam-
ples were collected from all suspected cases of TB, per
standard of care. Demographic information and clinical
history (including vaccinations and comorbidities) were
collected from patient interviews.
The study protocol received approval from the institutional
review board at St. John’s Research Institute (Bangalore,
Karnataka, India). All study participants provided informed
consent prior to any data collection. All analyses occurred
subsequent to data de-identification (Additional file 1).
Assessment of outcomes
Active and latent TB were assessed in sputum and
blood samples by three techniques: Xpert (Cepheid,
Sunnyvale, California, United States), AFB, and QFT-G
(Cellestis Limited, Carnegie, Victoria, Australia). The
presence of Mycobacterium tuberculosis (MTB) in spu-
tum was evaluated by Xpert and AFB. For Xpert assays,
sputum specimens were decontaminated with N-acetyl-
L-cysteine-sodium hydroxide, and processed according
to manufacturer instructions. As a fully automated real-
time multiplex polymerase chain reaction assay that is
based on the GeneXpert platform, Xpert also assessed
rifampin resistance (via rpoB gene mutations). AFB was
based on standard protocol for Ziehl-Neelsen staining
with conventional light microscopy.
Additionally, QFT-G measured the interferon-gamma
response triggered by incubation with two MTB anti-
gens (early secretory antigenic target-6; culture filtrate
protein-10). QFT-G is recommended as an aid for diag-
nosing TB infection, as it can serve as an alternative to
tuberculin skin tests but does not distinguish between
latent versus active TB. For the QFT-G assay, blood
was initially collected in QFT-G tubes. Samples were
centrifuged to obtain plasma, processed according to
manufacturer protocol, and assessed by enzyme-linked
immunosorbent assay.
Assessment of exposure and other covariates
Diabetes status was based on patient self-report. Human
immunodeficiency virus (HIV) status was assessed by a
rapid HIV test (TRI-DOT; J. Mitra & Co. Pvt. Ltd.; New
Delhi, India), per standard Revised National Tubercu-
losis Control Programme guidelines for individuals with
suspected TB.
Statistical analyses
Relative diagnostic performance was assessed by cal-
culating sensitivity, specificity, predictive values, and
AUC (by receiver operator characteristic [ROC] curve
visualization). Xpert results were considered as the
gold standard for comparing conventional TB diagnostics.
Study participants were categorized as either previous or
new cases, based on whether anti-TB treatment was previ-
ously received. Statistical analyses were conducted with
SAS software (version 9.4; SAS Institute Inc., Cary, NC,
USA); two-tailed P-values <0.05 were considered statisti-
cally significant.
Patient demographic and health characteristics were
reported as means (standard deviations [SDs]) or per-
centages. Group differences were assessed by t-tests
(continuous variables with normal distribution; Satterwaite
method for unequal variance) or Mantel-Haenszel χ2-
tests (categorical variables). Potential covariates were
identified a priori, based on previous literature. Ini-
tially, associations between potential covariates were
assessed by univariate log-binomial regression models;
variables with p < 0.2 were included in the full model.
Subsequently, only variables with p < 0.05 were retained
in the final multivariate log-binomial regression model.
Results
Among 304 study participants with suspected TB,
63.8 % had TB confirmed by Xpert, 10.9 % had diabetes,
and 2.6 % were living with HIV (Table 1). Overall,
23.7 % were female, which did not differ significantly
when stratified by diabetes (p = 0.72) or TB (p = 0.41).
The average age of patients was 38.3 years (SD 11.5).
Patients with diabetes were older than those without
diabetes (p = 0.01); those with and without TB (based
on Xpert) were similar in age (p = 0.08). The majority
(87.5 %) had never previously received anti-TB treatment.
Among patients with confirmed TB (by Xpert; n = 194),
11.3 % had diabetes and 10.8 % were rifampin resistant
(Table 1). 27.3 % of patients with diabetes had rifampin
resistance, compared to 8.8 % of patients with no dia-
betes (p < 0.01). Rifampin resistance was associated with
diabetes (adjusted risk ratio [aRR] 2.96 [95 % confi-
dence intervals {CI}: 1.30-6.74]), previous TB treatment
(aRR 3.33 [95 % CI 1.53–7.22]), and positive AFB (aRR
3.14 [95 % CI: 1.03–9.58]) (Table 2).
Considering Xpert as the gold standard, AFB had
72.2 % (95 % CI: 65.3–78.4) sensitivity and 96.4 % (95 %
CI: 91.0–99.0) specificity (Additional file 2: Table S1).
In contrast, QFT-G had higher sensitivity (82.5 % [95 %
CI: 76.8–88.2], but lower specificity (37.0 % [95 % CI:
27.1–46.8]; Additional file 2: Table S1). With Xpert as
the reference, AFB had higher positive predictive value
(PPV; 97.2 % [95 % CI: 93.0–99.2]) and negative pre-
dictive value (NPV; 66.3 % [95 % CI: 58.4–73.5]) than
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Table 1 Demographic and baseline health characteristics of patientsa
Overall TBb
Y N
n = 194 n = 110
N Mean (SD) Mean SD Mean SD
Agec 304 38.3 (11.5) 37.4 11.3 39.8 11.6
N % N % N %
Female 72 23.7 43 22.2 29 26.4
Male 232 76.3 151 77.8 81 73.6
Time Since Previous TB Treatment (years)
1 11 3.6 9 4.6 2 1.8
1.5 1 0.3 1 0.5 0 0.0
2 10 3.3 7 3.6 3 2.7
3 8 2.6 4 2.1 4 3.6
4 3 1.0 1 0.5 2 1.8
5 4 1.3 2 1.0 2 1.8
7 1 0.3 0 0.0 1 0.9
None 266 87.5 170 87.6 96 87.3
Rifampin Resistance
Y — — 21 10.8 — —
N — — 172 88.7 — —
Diabetesd
Y 33 10.9 22 11.3 11 10.0
N 271 89.1 172 88.7 99 90.0
HIV
Y 8 2.6 8 4.1 — —
N 186 61.2 186 95.6 — —
aMissing values included: rifampin resistance (n = 111); HIV (n = 110). Reported percentages include missing values in the denominators.
bTB status determine by Xpert MTB/RIF
cMedian 40; min 18; max 60; IQR 28–47
dAccording to patient self-report
Table 2 Factors associated with rifampin-resistant Mycobacterium tuberculosis based on Xpert MTB/RIF assay
Rifampin resistance
Univariate Multivariate
RR (95 % CI) P aRR (95 % CI) P
Age (years) 0.99 (0.96–1.03) 0.78 — —
Sex (male) 0.58 (0.18–1.88) 0.37 — —
Diabetesa 3.11 (1.35–7.17) <0.01 2.96 (1.30–6.74) <0.01
Previous TB Treatment 3.52 (1.58–7.84) <0.01 3.33 (1.53–7.22) <0.01
BCG Vaccination 0.60 (0.26–1.36) 0.22 — —
TB Symptoms (weeks)b 1.00 (0.97–1.03) 0.81 — —
QFT-G 2.02 (0.50–8.22) 0.33 — —
AFB 3.60 (0.87–14.91) 0.08 3.14 (1.03–9.58) 0.05
Abbreviations: AFB Acid-fast bacilli sputum smear microscopy, BCG Bacille Calmette-Guérin, CI confidence interval, TB tuberculosis, QFT-G Quantiferon-TB Gold
In-Tube, RR risk ratio, aRR adjusted risk ratio
aAccording to patient self-report
bTime (weeks) since initial onset of symptoms suggestive of TB, including persistent cough, fever, weight loss
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QFT-G (PPV 70.9 % [95 % CI: 64.5–77.2], NPV 53.1 %
[95 % CI: 40.9–65.4]; Additional file 2: Table S1). Simi-
larly, AFB (relative to Xpert) had a higher AUC (0.84;
Additional file 3: Figure S1A) compared to QFT-G
(0.60; Additional file 3: Figure S1B).
Discussion
We observed an association between rifampin resistance
and diabetes among adult patients with active TB in an
urban setting of India. This finding corroborates previ-
ous studies that showed greater risk of MDR-TB among
patients with TB and diabetes, compared to those with-
out diabetes [8]. Moreover, other studies confirmed asso-
ciations between Type 2 diabetes and MDR-TB [9] as
well as delayed time to sputum smear conversion [10].
Another study among patients with TB found approxi-
mately 50 % reductions of rifampin and isoniazid plasma
concentrations (both p < 0.05), among patients with dia-
betes, compared to patients without diabetes [11]. How-
ever in contrast, other studies showed no associations
between TB drug resistance and diabetes, or differences
in treatment outcomes based on TB drug resistance and
diabetes status [12].
Rifampin resistance was observed in 10.8 % of patients
with TB in this study. Directly comparing this estimate
to other estimates is challenging given the limited recent
nationally-representative data from India [13]. For ex-
ample, among patients with suspected TB in Maharash-
tra, rifampin resistance ranged between 9 % (rural) to
51 % (urban) [14].
The comparative performances of AFB smear and
QFT-G (relative to Xpert) have also been considered
by previous literature as a diagnostic test for active
TB. A meta-analysis found that for the detection of
active TB in blood and extrasanguinous fluids, QFT-G
had a pooled sensitivity of 80 % (95 % CI: 75–84 %)
for culture-confirmed cases [15], which is similar to
the 82.5 % sensitivity in our study. However the observed
specificity was much lower (37 %). ROC curves also re-
flect that QFT-G should not be used in diagnosing TB
in this setting and AFB smear is less than ideal. Our
findings therefore support the continued need for im-
proved diagnostic capacity in order to effectively ad-
dress TB.
Study limitations included the cross-sectional data,
which does not allow for causal inference or the con-
sideration of time (as well as disease progression). Al-
though we controlled for certain covariates, residual
confounding remains possible. This study was a sec-
ondary analyses of data collected for a parent study.
Consequently the limitations included the unavailability of
TB culture data and any biological indicator of diabetes
(glycosylated hemoglobin, fasting glucose). Although dia-
betes was based on self-report and not confirmed by
another biological indicator, this would likely result in
non-differential misclassification. Additionally, these
data were insufficient to distinguish between Type 1
versus Type 2 diabetes or account for appropriate treat-
ment. However in contrast, a validity study showed that
self-report of diabetes is fairly consistent among pa-
tients receiving treatment [16].
Strengths of this study include that TB and rifampin
resistance were detected by Xpert, which has high sen-
sitivity (>90 %) and specificity (>95 %) for rifampin de-
tection [17], and was endorsed by the WHO in 2010.
Rifampin resistance has been considered a potential in-
dicator for MDR-TB [18], given that a large proportion
of TB strains with rifampin resistance are also isoniazid
resistant. Furthermore, rifampin is a key antitubercu-
lous drug in standard TB treatment.
Conclusions
In rural Andhra Pradesh, self-reported diabetes was as-
sociated with 3.0-fold higher risk of rifampin resistance
among patients with confirmed TB. AFB had lower sen-
sitivity (72.2 vs. 82.5 %) and higher specificity (96.4 vs.
37.0 %) compared to QFT-G for diagnosing TB.
Our findings on the association between diabetes and
rifampin resistance highlight the need for integrated
diabetes surveillance in TB programs, particularly in
similar settings going through the epidemiological tran-
sition. Furthermore, quantifying the disparities in re-
sults of different TB diagnostic methods is critical for
establishing a global research environment in which re-
sults from different studies can be accurately compared
to draw conclusions.
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